Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.

Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Citi 2024 Global Healthcare Conference.

Merck to Participate in the Citi 2024 Global Healthcare Conference

On Monday, Merck & Co Inc MRK revealed topline results from the Phase 3 ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality.

Why Is Merck Stock Trading Higher On Monday?

American Tower

KeyCorp

Paramount Global

Pfizer

SBA Communications

Seagate Technology Holdings PLC

Vistra Energy

Nvidia reported third-quarter profit that doubled — putting it near the top of the S&P 500's growth. But look for profit growth elsewhere.

Nvidia's Profit Ruled Last Quarter — Now It's These 8 Stocks' Turn

Merck said on Monday its drug, Winrevair, helped significantly reduce the risk of death in patients with a rare condition which causes high blood pressure in the lungs, months after it secured approval in the United States.

Merck's therapy for rare lung condition shown to help reduce risk of death in study

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis.

Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Recommends Rejection of TRC Capital's “Mini-Tender” Offer.

Merck Recommends Rejection of TRC Capital's “Mini-Tender” Offer

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

In today's market, many investors are distracted by hype. But the real value lies in stocks that provide strong, consistent dividend yields without the noise. Instead of chasing the latest trends, focusing on high-yield dividend stocks that are undervalued is a smart strategy for building wealth over time. Two of my picks offer both deep value and high yields, making them standout opportunities for any dividend-focused portfolio.

Not A Banana: 2 (Special) Dividend Stocks Offering Ultra-Deep Value

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference.

Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's WELIREG Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors.

Merck's WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

Emerson Electric

RAHWAY, N.J.--(BUSINESS WIRE)--Surendralal Karsanbhai Elected to Merck Board of Directors.

Surendralal Karsanbhai Elected to Merck Board of Directors

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

Merck Stock Trades Near 52-Week Low: What's Next for Investors?

Merck & Co., Inc. (NYSE:MRK ) Jefferies London Healthcare Conference November 21, 2024 6:30 AM ET Corporate Participants Joe Romanelli - President, Human Health International Marjorie Green - SVP and Head of Oncology, Global Clinical Development, Merck Research Laboratories Conference Call Participants Akash Tewari - Jefferies Akash Tewari Good morning, everyone Day 3. We're at the end of it.

Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference

2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and investigational medicines across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from Dec. 7-10. Data being shared at the meeting will showcase the company's continued progress in advancing clinical research for Merck's expanding and diverse pipeline of inv.

Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2025 Dividend.

Merck Announces First-Quarter 2025 Dividend

In recent weeks, financial participants have remained pessimistic about Merck's development prospects, partly due to the nomination of Robert F. Kennedy Jr. as head of HHS. However, I believe Mr. Market overreacted to this news, given the strong performance of Merck's oncology franchise in recent quarters. So, sales of Keytruda amounted to $7.43 billion for the three months ended September 30, 2024, an increase of 17.2% year-over-year.

Merck: Seriously Undervalued At Peak Pessimism (Rating Upgrade)

The company has been preparing for the 2028 expiration of its patents protecting Keytruda.

Merck's Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again.

The news may help Merck retain sales of Keytruda, which is the world's best-selling drug.

Merck says blockbuster cancer drug met main goals in trial of new under-the-skin formulation

Merck said on Tuesday a study showed that its injectable version of cancer drug Keytruda was not inferior to the currently approved intravenous formulation of its treatment, likely making it even more accessible and easier to administer.

Merck says Keytruda injection on par with approved IV version in trial

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the pivotal Phase 3 MK-3475A-D77 trial. The trial is evaluating the noninferiority of subcutaneous administration of pembrolizumab, Merck's anti-PD-1 therapy, available for intravenous use as KEYTRUDA®, together with berahyaluronidase alfa, a hyaluronidase variant developed and manufactured by Alteogen Inc. (MK-3475A; “subcutaneous pembrolizumab”).

Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant pleural mesothelioma.

Merck Gets Positive CHMP Opinion for Keytruda in Mesothelioma

This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. I expect 10 companies to announce their annual increases in the second half of November, including modest increases from Merck and a 10%+ increase from Raymond James Financial. Hormel Foods is expected to announce its 59th consecutive year of dividend growth, highlighting its long-term commitment to dividend increases.

Merck Among 10 Companies To Announce Annual Dividend Increases In Second Half Of November

CMS Energy

Mondelez

PepsiCo

The October producer price index edged up to 2.4%. Ongoing inflation could temper how many rate cuts are in line for 2025.

News for Merck Stock (MRK)